Implementation and evaluation of a breast cancer disease model using real-world claims data in Germany from 2010 to 2020

• Verfasst von: Dannehl, Dominik [VerfasserIn]
• Verfasst von: Au, Alexandra von [VerfasserIn]
• Verfasst von: Engler, Tobias [VerfasserIn]
• Verfasst von: Volmer, Léa [VerfasserIn]
• Verfasst von: Gutsfeld, Raphael [VerfasserIn]
• Verfasst von: Englisch, Johannes Felix [VerfasserIn]
• Verfasst von: Hahn, Markus [VerfasserIn]
• Verfasst von: Hawighorst, Sabine [VerfasserIn]
• Verfasst von: Chaudhuri, Ariane [VerfasserIn]
• Verfasst von: Bauer, Armin [VerfasserIn]
• Verfasst von: Wallwiener, Markus [VerfasserIn]
• Verfasst von: Ţăran, Florin-Andrei [VerfasserIn]
• Verfasst von: Wallwiener, Diethelm [VerfasserIn]
• Verfasst von: Brucker, Sara [VerfasserIn]
• Verfasst von: Wallwiener, Stephanie [VerfasserIn]
• Verfasst von: Hartkopf, Andreas [VerfasserIn]
• Verfasst von: Dijkstra, Tjeerd Maarten Hein [VerfasserIn]
• Titel: Implementation and evaluation of a breast cancer disease model using real-world claims data in Germany from 2010 to 2020
• Verf.angabe: by Dominik Dannehl, Alexandra von Au, Tobias Engler, Léa Louise Volmer, Raphael Gutsfeld, Johannes Felix Englisch, Markus Hahn, Sabine Hawighorst-Knapstein, Ariane Chaudhuri, Armin Bauer, Markus Wallwiener, Florin-Andrei Taran, Diethelm Wallwiener, Sara Yvonne Brucker, Stephanie Wallwiener, Andreas Daniel Hartkopf and Tjeerd Maarten Hein Dijkstra
• Jahr: 2024
• Umfang: 15 S.
• Illustrationen: Diagramme
• Titel Quelle: Enthalten in: Cancers
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2024
• Band/Heft Quelle: 16(2024), 8, Artikel-ID 1490, Seite 1-15
• ISSN Quelle: 2072-6694
• DOI: doi:10.3390/cancers16081490
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1888243929

Abstract

Breast cancer is the leading cause of cancer-related mortality among women in Germany and worldwide. This retrospective claims data analysis utilizing data from AOK Baden-Wuerttemberg, a major statutory German health insurance provider, aimed to construct and assess a real-world data breast cancer disease model. The study included 27,869 female breast cancer patients and 55,738 age-matched controls, analyzing data from 2010 to 2020. Three distinct breast cancer stages were analyzed: Stage A (early breast cancer without lymph node involvement), Stage B (early breast cancer with lymph node involvement), and Stage C (primary distant metastatic breast cancer). Tumor subtypes were estimated based on the prescription of antihormonal or HER2-targeted therapy. The study established that 77.9% of patients had HR+ breast cancer and 9.8% HER2+; HR+/HER2- was the most common subtype (70.9%). Overall survival (OS) analysis demonstrated significantly lower survival rates for stages B and C than for controls, with 5-year OS rates ranging from 79.3% for stage B to 35.4% for stage C. OS rates were further stratified by tumor subtype and stage, revealing varying prognoses. Distant recurrence-free survival (DRFS) analysis showed higher recurrence rates in stage B than in stage A, with HR-/HER2- displaying the worst DRFS. This study, the first to model breast cancer subtypes, stages, and outcomes using German claims data, provides valuable insights into real-world breast cancer epidemiology and demonstrates that this breast cancer disease model has the potential to be representative of treatment outcomes.